Scalable process technologies for human pluripotent stem cells (hPSCs) expansion and differentiation.

Area of Science:

• Regenerative Medicine
• Biotechnology
• Cell Manufacturing

Background:

• Human pluripotent stem cells (hPSCs) are a key resource for regenerative medicine, with over 100 clinical trials initiated.
• Current hPSC manufacturing methods need to evolve towards industry-scale, clinically compliant processes for routine therapeutic use.

Purpose of the Study:

• To review recent advancements in bioprocessing for human pluripotent stem cell (hPSC) manufacturing.
• To highlight strategies for scalable cultivation, differentiation, and downstream processing of hPSCs.

Main Methods:

• Focus on 3D suspension culture bioprocessing for hPSC expansion and directed differentiation.
• Integration of upstream and downstream processes for GMP-ready production.
• Discussion of industrial-scale bioprocessing metrics beyond cell yield, including productivity and reproducibility.

Main Results:

• Suspension culture systems enable standardized and intensified hPSC cultivation and differentiation.
• Integration of upstream expansion and directed differentiation protocols is crucial for coherent production.
• AI and machine learning show promise for data-rich, controlled bioreactor-based manufacturing.

Conclusions:

• Bioreactor-based hPSC manufacturing is transitioning towards controlled, data-driven processes.
• AI/ML can enhance process control, reduce batch failures, and ensure consistent product definition.
• Future hPSC therapies depend on economically viable and reproducible manufacturing platforms.